1Chute JP, Chen T, Feigal E, et al. Twenty years of phase Ⅲ trials for patients with extensive-stage small-cell lung cancer: perceptible progress[J]. J Clin Oncol, 1999, 17(6) : 1794-1801.
2Herbst RS,Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications[J]. J Clin Oncol, 2005, 23(14):3243-3256.
3Sandler A SS,Dowlati A. A phase Ⅱ study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group [A]. Proc Am Soc Clin Oncol [C]. Chicago: ASCO, 2007. 400S.
4Ready N DA,Wang XF.CALGB 30306: a phase Ⅱ study of cisplatin (C), Irinotecan (i) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) [A]. Proc Am Soc Clin Oncol [C]. Chicago: ASCO, 2007. 400S.
5Hal Barton. Important drug warning regarding avastin (bevacizumab) [EB/OL]. http://www.gene.com/gene/products/ imformation/pdf/avastin_te_letter.pdf, 2007.
6Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer[J].Cancer Res,2005,65(10):4389-4400.
7Arnold Am,Seymour L, Smylie M, et al. Phase Ⅱ study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR. 20[J]. J Clin Oncol, 2007, 25(27):4278-4284.
8Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [J]. N Engl J Med, 1999(21):1565-1571.
9Dowlati A, Subbiah S, Cooney M, et al. Phase Ⅱ trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy[J]. Lung Cancer, 2007, 56(3):377-381.
10Lee SM, Woll PJ, James LE, et al. A phase Ⅱ randomized, double blind, placebo controlled trial of etoposide/ carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC)[A]. the 12d' World Conference on Lung Cancer[C]. Seoul: WCLC, 2007. $306.
6Jagasia MH,Langer CJ,Johson DH. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer:A multicenter phaseⅡstudy[J].Clinical Cancer Research,2001,(01):68-73.
7Hirose T,Horichi N,Ohmori T. PhaseⅡstudy of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer[J].Lung Cancer,2003,(03):333-338.
8Mascaux C,Paesmans M,Berghmans T. European Lung Cancer Working Party (ELCWP).A systematic review of the role of etoposide and cisplatin in the chemotherapy of small-cell lung cancer with methodology assessment and meta-analysis[J].Lung Cancer,2000,(01):23-36.
9Sundstrom S,Bremnes RM,Kaasa S. Cisplatin and etoposide regimen is superior to cyclophosphamide,epirubicin,and vincristine regimen in small-cell lung cancer:results from a randomized phase III trial with 5 years' follow-up[J].Journal of Clinical Oncology,2002,(24):4665-4672.
10Ettinger DS,Jotte R,Lorigan P. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer[J].Journal of Clinical Oncology,2010,(15):2598-2603.
